MA30720B1 - Analogues de 2-phenoxypyrimidinone - Google Patents

Analogues de 2-phenoxypyrimidinone

Info

Publication number
MA30720B1
MA30720B1 MA31732A MA31732A MA30720B1 MA 30720 B1 MA30720 B1 MA 30720B1 MA 31732 A MA31732 A MA 31732A MA 31732 A MA31732 A MA 31732A MA 30720 B1 MA30720 B1 MA 30720B1
Authority
MA
Morocco
Prior art keywords
phenoxypyrimidinone
ligands
compounds
analogues
methods
Prior art date
Application number
MA31732A
Other languages
English (en)
Inventor
Rajagopal Bakthavatchalam
Scott Michael Capitosti
Jianjun Xu
Bertrand L Chenard
Manuka Ghosh
Charles A Blum
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of MA30720B1 publication Critical patent/MA30720B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)

Abstract

L'INVENTION CONCERNE DES ANALOGUES DE LA 2-PHÉNOXYPYRIMIDINONE, DE FORMULE : DANS LAQUELLE LES VARIABLES SONT TELLES QUE DÉCRITES ICI. DE TELS COMPOSÉS SONT DES LIGANDS QUI PEUVENT ÊTRE UTILISÉS POUR MODULER L'ACTIVITÉ DE RÉCEPTEURS PARTICULIERS IN VIVO OU IN VITRO ET QUI SONT PARTICULIÈREMENT UTILES DANS LE TRAITEMENT D'AFFECTIONS ASSOCIÉES À L'ACTIVATION PATHOLOGIQUE DE RÉCEPTEURS CHEZ DES HUMAINS, DES ANIMAUX DE COMPAGNIE DOMESTIQUÉS ET LE BÉTAIL. L'INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES ET DES PROCÉDÉS D'UTILISATION DE TELS COMPOSÉS POUR TRAITER DE TELS TROUBLES, AINSI QUE DES PROCÉDÉS D'UTILISATION DE TELS LIGANDS POUR DES ÉTUDES DE LOCALISATION DE RÉCEPTEURS.
MA31732A 2006-08-23 2009-03-23 Analogues de 2-phenoxypyrimidinone MA30720B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82325806P 2006-08-23 2006-08-23

Publications (1)

Publication Number Publication Date
MA30720B1 true MA30720B1 (fr) 2009-09-01

Family

ID=39107411

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31732A MA30720B1 (fr) 2006-08-23 2009-03-23 Analogues de 2-phenoxypyrimidinone

Country Status (22)

Country Link
US (2) US8003656B2 (fr)
EP (1) EP2061794B1 (fr)
JP (1) JP5421108B2 (fr)
KR (1) KR20090043583A (fr)
CN (2) CN101506210A (fr)
AU (1) AU2007288203B2 (fr)
BR (1) BRPI0716582A2 (fr)
CA (1) CA2660957C (fr)
CO (1) CO6150167A2 (fr)
CR (1) CR10675A (fr)
EA (1) EA200900330A1 (fr)
ES (1) ES2399928T3 (fr)
GT (1) GT200900040A (fr)
IL (1) IL197043A0 (fr)
MA (1) MA30720B1 (fr)
MX (1) MX2009002066A (fr)
NI (1) NI200900023A (fr)
NO (1) NO20091182L (fr)
SV (1) SV2009003173A (fr)
TW (1) TW200825089A (fr)
WO (1) WO2008024438A2 (fr)
ZA (1) ZA200901163B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0509573D0 (en) * 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
WO2008024438A2 (fr) 2006-08-23 2008-02-28 Neurogen Corporation Analogues de la 2-phénoxypyrimidinone
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
SG11201601616SA (en) * 2013-09-09 2016-04-28 Peloton Therapeutics Inc Aryl ethers and uses thereof
WO2016023830A1 (fr) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Dérivés de pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016145045A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions s'utilisant dans le traitement du glioblastome
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016144826A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Pyridines substituées et leurs utilisations
WO2016168510A1 (fr) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Thérapie combinée avec un inhibiteur de hif-2-alpha et un agent immunothérapeutique, et applications corresponantes
WO2020146449A1 (fr) * 2019-01-08 2020-07-16 Texas Tech University System Analogues de petites molécules de la protéine e4orf1 dans le traitement et la prévention de troubles métaboliques

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
EP0807633B1 (fr) 1996-05-15 2002-11-06 Pfizer Inc. (5,6)-Pyrimidin-4-ones condensées à hétéroaryle, substituées en 2,3
DE69808282T2 (de) 1997-05-08 2003-05-15 Aventis Cropscience Uk Ltd., Hauxton Verwendung von Thienopyrimidinen als Fungizide
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
AU2002214546A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
WO2002064598A1 (fr) 2001-02-14 2002-08-22 Warner-Lambert Company Llc Derives de thieno'2,3-d pyrimidinone utilises comme inhibiteurs de metalloproteinases matricielles
EP1377576A2 (fr) 2001-03-26 2004-01-07 Novartis AG Derivee de la pyridine
US20070125454A1 (en) * 2001-09-28 2007-06-07 Konrad Eipper High-strength duplex/triplex steel for lightweight construction and use thereof
JP2005513154A (ja) 2001-12-26 2005-05-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 尿素誘導体
ATE533743T1 (de) 2002-05-17 2011-12-15 Janssen Pharmaceutica Nv Harnstoffderivate von aminotetralin als modulatoren des vanilloid-rezeptors vr1
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
AU2003273856A1 (en) 2002-09-24 2004-04-19 Bayer Healthcare Ag Vr1 antagonists for the treatment of urological disorders
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
US20040132732A1 (en) 2002-10-21 2004-07-08 Wei Han Quinazolinones and derivatives thereof as factor Xa inhibitors
CA2518465A1 (fr) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Inhibiteurs de dipeptidyle peptidase
CA2545725A1 (fr) * 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Pyrimidine-4-(3h)-ones bicycliques, leurs analogues et derives modulant la fonction du recepteur de vanilloide-1 (vr1)
GB0326633D0 (en) 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
US7544803B2 (en) 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
GB0509573D0 (en) * 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
US20090298856A1 (en) * 2005-05-11 2009-12-03 Rebecca Elizabeth Brown 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1)
CN1318429C (zh) * 2005-07-25 2007-05-30 华中师范大学 具有杀菌活性的取代噻吩并[3',2':5,6]吡啶并[4,3－d]嘧啶－4(3H)－酮及制备
EP1954283A2 (fr) 2005-11-04 2008-08-13 Hydra Biosciences, Inc. Composés destinés à moduler la fonction de trpv3
EP2061470A4 (fr) 2006-08-23 2010-10-06 Neurogen Corp Dérivés de la pyrimidinone substitués par un halogénoalkyle
WO2008024438A2 (fr) 2006-08-23 2008-02-28 Neurogen Corporation Analogues de la 2-phénoxypyrimidinone
AU2007325940A1 (en) 2006-11-06 2008-06-05 Neurogen Corporation Cis-cyclohexyl substituted pyrimidinone derivatives
WO2008156607A1 (fr) 2007-06-12 2008-12-24 Neurogen Corporation Pyrimidinones substituées
WO2009100403A1 (fr) 2008-02-07 2009-08-13 Neurogen Corporation Aryl pyrimidinones substitués
WO2009121036A2 (fr) 2008-03-27 2009-10-01 Neurogen Corporation Dérivés d'arylpyrimidone substitués

Also Published As

Publication number Publication date
AU2007288203B2 (en) 2013-01-17
CN104292229A (zh) 2015-01-21
WO2008024438A2 (fr) 2008-02-28
JP2010502576A (ja) 2010-01-28
SV2009003173A (es) 2010-08-10
EP2061794A4 (fr) 2010-09-08
CO6150167A2 (es) 2010-04-20
MX2009002066A (es) 2009-03-06
CA2660957A1 (fr) 2008-02-28
US20120208829A1 (en) 2012-08-16
BRPI0716582A2 (pt) 2013-10-08
ES2399928T3 (es) 2013-04-04
US8003656B2 (en) 2011-08-23
NO20091182L (no) 2009-05-14
TW200825089A (en) 2008-06-16
WO2008024438A3 (fr) 2008-11-27
US20090069347A1 (en) 2009-03-12
JP5421108B2 (ja) 2014-02-19
CN101506210A (zh) 2009-08-12
AU2007288203A1 (en) 2008-02-28
EA200900330A1 (ru) 2009-08-28
EP2061794B1 (fr) 2012-12-05
US8759361B2 (en) 2014-06-24
IL197043A0 (en) 2009-11-18
CA2660957C (fr) 2016-10-11
NI200900023A (es) 2010-03-05
EP2061794A2 (fr) 2009-05-27
ZA200901163B (en) 2010-08-25
KR20090043583A (ko) 2009-05-06
GT200900040A (es) 2010-03-16
CR10675A (es) 2009-04-17

Similar Documents

Publication Publication Date Title
MA54229B1 (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
WO2006049941A3 (fr) Diaryl urees, antagonistes du cb1
MXPA05006123A (es) Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina.
MA31683B1 (fr) Composes et procedes pour moduler fxr
WO2007140383A3 (fr) Sulfonamides spirocycliques et composés apparentés
MA28660B1 (fr) Composes et compositions en tant que modulateurs de ppar
TW200716594A (en) Substituted heteroaryl CB1 antagonists
WO2007101007A8 (fr) Heterocycles sulfonyl aryliques
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
TW200510373A (en) Substituted quinolin-4-ylamine analogues
WO2007146761A3 (fr) Diaryl pyrimidinones et composés associés
MA33299B1 (fr) Nouvelle formulation de naproxène
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
EA200900330A1 (ru) Аналоги 2-феноксипиримидинона
MA32798B1 (fr) Acides naphtylacétiques
WO2005023807A3 (fr) Derives de quinazolin-4-ylamine bicyclique substitue
TW200605889A (en) Substituted biaryl piperazinyl-pyridine analogues
WO2008024433A3 (fr) Dérivés de la pyrimidinone substitués par un halogénoalkyle
WO2008033739A3 (fr) Dérivés de benzimidazolecarboxamide
WO2008066664A3 (fr) Dérivés de pyrimidinone substitués par cis-cyclohexyle
WO2006076646A3 (fr) Analogues de quinolin-4-ylamine à substitution hétéroaryle
WO2006042289A3 (fr) Analogues de biaryl quinoline-4-ylamine a substitution
WO2005084401A3 (fr) Analogues des purines à substitution aryle
WO2006089076A3 (fr) Thiazole amides, imidazole amides et analogues associes
WO2007133820A3 (fr) Diaryl triazolones comme antagonistes de cb1